Clinical trial
Irofulven in Treating Patients With Metastatic Breast Cancer
NCT00003796 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003796 |
|---|---|
| Title | Irofulven in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Study of MGI-114 in Patients With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Enrollment | 32 |
| Start date | May 1, 1999 |
| Primary completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: